ニトロチロシン濃度と心血管疾患の関連性,スタチン療法による調節
Mehdi H Shishehbor1, Ronnier J Aviles, Marie-Luise Brennan
1Department of Cell Biology, and the Center for Cardiovascular Diagnostics and Prevention, the Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
JAMA
|April 4, 2003
まとめ
ニトロチロシン濃度の上昇は,冠動脈疾患 (CAD) のリスクが高いことを示します. スタチンの治療はこれらのレベルを効果的に低下させ,酸化窒素由来酸化物質が炎症と動脈硬化に作用することを示唆しています.
科学分野:
- 心血管医学 心血管医学
- バイオケミストリー バイオケミストリー
- 炎症の研究 炎症の研究
背景:
- 酸化窒素由来の酸化剤は,炎症と動脈硬化症の発達を結びつける可能性があります.
- 酸化物質変化のマーカーであるニトロチロシンは,動脈硬化病変とLDLで発見されています.
研究 の 目的:
- システミックなニトロチロシン濃度と冠動脈疾患 (CAD) の罹患率の関連性を調査する.
- スタチンの治療がニトロチロシン濃度に影響するかどうかを判断する.
主な方法:
- 症例対照研究では,100人のCAD患者と108人の対照群のニトロチロシン濃度を比較した.
- ある介入研究では,高コレステロール血症の患者35人をアトルバスタチン (10 mg/日) で12週間治療した.
主要な成果:
- ニトロチロシン濃度は,CAD患者において有意に高かった (P<.001).
- ニトロチロシン四分数の高さは,多変量調整 (OR,4.4;P<.001) の後でも,CADの確率の増加と関連していました.
- スタチンの治療は,リポタンパク質やCRPの変化に関係なく,ニトロチロシン濃度を25% (P<0.02) 低下させた.
結論:
- システミックなニトロチロシン濃度は,CADの存在と関連しています.
- スタチンの治療はニトロチロシンレベルを調節することができ,CADの病原性における酸化物質による酸化物質の役割を示唆しています.
- この発見は,動脈硬化リスク評価とスタチンの抗炎症効果のモニタリングにおけるニトロチロシンの可能性を示唆しています.
さらに関連する動画
関連する概念動画
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.